TY - JOUR
T1 - Community transition at younger ages contributes to good cognitive function outcomes in long-term hospitalized patients with schizophrenia spectrum disorder
T2 - A 15-year follow-up study with group-based trajectory modeling
AU - Kida, Hisashi
AU - Niimura, Hidehito
AU - Nemoto, Takahiro
AU - Ryu, Yonosuke
AU - Sakuma, Kei
AU - Mimura, Masaru
AU - Mizuno, Masafumi
N1 - Funding Information:
M. Mizuno has received honoraria for lectures from Astellas Pharma, Daiichi Sankyo, Eisai, Janssen Pharmaceutical, Kyowa Hakko Kirin, Mitsubishi Tanabe Pharma, Mochida Pharmaceutical, Meiji Seika Pharma, Merck Sharp and Dohme, Otsuka Pharmaceutical, and Sumitomo Dainippon Pharma, and received research funding from Daiichi‐Sankyo, Eisai, Meiji Seika Pharma, Mochida Pharmaceutical, Otsuka Pharmaceutical, Pfizer, and Sumitomo Dainippon Pharma. M. Mimura has received grants and/or speaker's honoraria from Asahi Kasei Pharma, Astellas Pharma, Daiichi Sankyo, Sumitomo Dainippon Pharma, Eisai, Eli Lilly, Fuji Film RI Pharma, Janssen Pharmaceutical, Kracie, Meiji‐Seika Pharma, Mochida Pharmaceutical, Merck Sharp and Dohme, Novartis Pharma, Ono Pharmaceutical, Otsuka Pharmaceutical, Pfizer, Shionogi, Takeda Pharmaceutical, Mitsubishi Tanabe Pharma, and Yoshitomi Yakuhin. T. Nemoto has received honoraria for lectures from Eisai, Janssen Pharmaceutical, Meiji Seika Pharma, Mochida Pharmaceutical, Otsuka Pharmaceutical, Sumitomo Dainippon Pharma, and Takeda Pharmaceutical. H. Niimura has received honoraria for lectures from Sumitomo Dainippon Pharma, Mochida Pharmaceutical, Otsuka Pharmaceutical, and Mitsubishi Tanabe Pharma. All other authors declare that they have no conflicts of interest.
Funding Information:
This work was supported by the Ministry of Education, Culture, Sports, Science, and Technology KAKENHI (Grant‐in‐Aid for Scientific Research [C], grant number: 26461772).
Publisher Copyright:
© 2019 The Authors. Psychiatry and Clinical Neurosciences © 2019 Japanese Society of Psychiatry and Neurology
PY - 2020/2/1
Y1 - 2020/2/1
N2 - Aim: Cognitive dysfunction is a core symptom of schizophrenia spectrum disorder, but the reported long-term cognitive outcomes are heterogeneous. This study aimed to elucidate the long-term trajectories of patients with schizophrenia spectrum disorder who transitioned to community dwelling with integrated care, and to identify predictors of successful community reintegration. Methods: After the closure of a psychiatric hospital, 78 patients with schizophrenia spectrum disorder (mean age: 54.6 years) were transferred to the community. We assessed patients' cognitive function over 15 years with the Mini-Mental State Examination (MMSE) and analyzed the scores every 3 years. Forty-four patients completed all assessments. Results: The mean MMSE score at discharge was 25.8, which changed to 26.8 after 3 years and 25.3 after 6 years. After 12 and 15 years, it had decreased significantly to 23.3 and 23.0, respectively. Group-based trajectory modeling identified two groups of patients: a ‘poor-outcome’ group (63.4%), showing a decline in scores after maintaining post-discharge levels for several years, and a ‘good-outcome’ group (36.6%), maintaining post-discharge scores after showing improved scores. Conclusion: Considering the significant difference in age between the aforementioned groups (P = 0.040), we suggest that community transitions at younger ages contribute to better cognitive function and adaptation to community life. Even middle-aged and elderly patients with chronic schizophrenia spectrum disorder showed improved or maintained cognitive function at least 3 years after discharge, and the good-outcome group maintained cognitive function over 15 years. Improvements were dominated primarily by age at discharge, with cognitive function being maintained longer in patients in the good-outcome group.
AB - Aim: Cognitive dysfunction is a core symptom of schizophrenia spectrum disorder, but the reported long-term cognitive outcomes are heterogeneous. This study aimed to elucidate the long-term trajectories of patients with schizophrenia spectrum disorder who transitioned to community dwelling with integrated care, and to identify predictors of successful community reintegration. Methods: After the closure of a psychiatric hospital, 78 patients with schizophrenia spectrum disorder (mean age: 54.6 years) were transferred to the community. We assessed patients' cognitive function over 15 years with the Mini-Mental State Examination (MMSE) and analyzed the scores every 3 years. Forty-four patients completed all assessments. Results: The mean MMSE score at discharge was 25.8, which changed to 26.8 after 3 years and 25.3 after 6 years. After 12 and 15 years, it had decreased significantly to 23.3 and 23.0, respectively. Group-based trajectory modeling identified two groups of patients: a ‘poor-outcome’ group (63.4%), showing a decline in scores after maintaining post-discharge levels for several years, and a ‘good-outcome’ group (36.6%), maintaining post-discharge scores after showing improved scores. Conclusion: Considering the significant difference in age between the aforementioned groups (P = 0.040), we suggest that community transitions at younger ages contribute to better cognitive function and adaptation to community life. Even middle-aged and elderly patients with chronic schizophrenia spectrum disorder showed improved or maintained cognitive function at least 3 years after discharge, and the good-outcome group maintained cognitive function over 15 years. Improvements were dominated primarily by age at discharge, with cognitive function being maintained longer in patients in the good-outcome group.
KW - Mini-Mental State Examination
KW - cognitive dysfunction
KW - community dwelling
KW - deinstitutionalization
KW - schizophrenia spectrum disorder
UR - http://www.scopus.com/inward/record.url?scp=85074759854&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85074759854&partnerID=8YFLogxK
U2 - 10.1111/pcn.12941
DO - 10.1111/pcn.12941
M3 - Article
C2 - 31599068
AN - SCOPUS:85074759854
SN - 1323-1316
VL - 74
SP - 105
EP - 111
JO - Psychiatry and Clinical Neurosciences
JF - Psychiatry and Clinical Neurosciences
IS - 2
ER -